{
    "clinical_study": {
        "@rank": "132957", 
        "arm_group": {
            "arm_group_label": "CAT-2003 or Placebo", 
            "arm_group_type": "Experimental", 
            "description": "All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess safety and efficacy of CAT-2003 in patients with\n      chylomicronemia. The study will evaluate the effects of CAT-2003 on fasting total and\n      chylomicron triglyceride levels, as well as postprandial total and chylomicron triglyceride\n      clearance.\n\n      This is a single-blind study. All patients will receive placebo for 1 week, and CAT-2003 for\n      12 weeks during the 13 week treatment period."
        }, 
        "brief_title": "Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lipoprotein Lipase Deficiency, Familial", 
            "Hyperlipoproteinemia Type I", 
            "Chylomicronemia, Familial", 
            "Hypertriglyceridemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipoproteinemias", 
                "Hypertriglyceridemia", 
                "Hyperlipoproteinemia Type I"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Familial Chylomicronemia (Fasting triglycerides \u2265 885 mg/dL at Screening and\n             documented history of plasma post-heparin LDL activity < 20% of normal or genetic\n             confirmation of homozygosity or compound heterozygosity for loss-of-function\n             mutations in familial chylomicronemia-causing genes) OR\n\n          -  Non-familial Chylomicronemia (Fasting triglycerides \u2265 442 mg/dL at Screening and\n             documented history of fasting triglycerides \u2265  885 mg/dL)\n\n        Key Exclusion Criteria:\n\n          -  History of any major cardiovascular event within 6 months of Screening\n\n          -  Type I diabetes mellitus or use of insulin\n\n          -  History of pancreatitis within 3 month of Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02098278", 
            "org_study_id": "CAT-2003-203"
        }, 
        "intervention": [
            {
                "arm_group_label": "CAT-2003 or Placebo", 
                "intervention_name": "CAT-2003", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CAT-2003 or Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chicoutimi", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G7H 7K9"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec City", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G1V 4M6"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Chylomicronemia", 
        "overall_contact": {
            "email": "clinical@catabasis.com", 
            "last_name": "Joanne Donovan, MD, PhD", 
            "phone": "(617) 349-1971"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent change from baseline in fasting triglycerides in patients with chylomicronemia", 
            "safety_issue": "No", 
            "time_frame": "12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02098278"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Absolute and percent change from baseline on postprandial total and chylomicron triglyceride levels", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Absolute and percent change from baseline on chylomicron triglyceride clearance", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Absolute and percent change from baseline in plasma non-HDL-C", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "13 weeks"
            }
        ], 
        "source": "Catabasis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Catabasis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}